Evangelidis P, Tragiannidis K, Vyzantiadis A, Evangelidis N, Kalmoukos P, Vyzantiadis T
Pathogens. 2025; 14(2).
PMID: 40005545
PMC: 11858289.
DOI: 10.3390/pathogens14020170.
Ow K
J Adv Pract Oncol. 2025; :1-15.
PMID: 39990042
PMC: 11840332.
DOI: 10.6004/jadpro.2025.16.7.6.
Rankin A, Duncan B, Allen C, Silbert S, Shah N
Cancer Metastasis Rev. 2024; 44(1):17.
PMID: 39674824
PMC: 11646216.
DOI: 10.1007/s10555-024-10227-1.
Czech M, Cuellar-Rodriguez J
Infect Dis Clin North Am. 2024; 39(1):121-144.
PMID: 39638718
PMC: 11786989.
DOI: 10.1016/j.idc.2024.11.008.
Matsuo T, Wurster S, Ivan D, Hicklen R, McConn K, Bagwell K
Open Forum Infect Dis. 2024; 11(11):ofae647.
PMID: 39507882
PMC: 11540139.
DOI: 10.1093/ofid/ofae647.
Shift from Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T Cell Therapy: Results from a Large Retrospective Cohort.
Melica G, Luna de Abia A, Shah G, Devlin S, Corona M, Fein J
Transplant Cell Ther. 2024; 31(1):36-44.
PMID: 39448032
PMC: 11780678.
DOI: 10.1016/j.jtct.2024.10.010.
A lesson from fatal invasive fungal infections after CAR-T cell therapy: a case report and literature review.
Hou Z, Meng D, Ruan M, Liang X, Ni J, Jifei D
Immunotherapy. 2024; 16(16-17):1021-1027.
PMID: 39373599
PMC: 11492695.
DOI: 10.1080/1750743X.2024.2404381.
Overview of infectious complications among CAR T- cell therapy recipients.
Arya S, Shahid Z
Front Oncol. 2024; 14:1398078.
PMID: 39026972
PMC: 11255439.
DOI: 10.3389/fonc.2024.1398078.
Infections associated with CAR-T cell therapy in patients with relapsed refractory multiple myeloma: Risks and prevention strategies.
An J, Zhao J, Zou P, Zhang Y, Wei J, Tian W
Cancer Med. 2024; 13(12):e7372.
PMID: 38923216
PMC: 11196838.
DOI: 10.1002/cam4.7372.
The Burden of Invasive Fungal Disease Following Chimeric Antigen Receptor T-Cell Therapy and Strategies for Prevention.
Little J, Kampouri E, Friedman D, McCarty T, Thompson 3rd G, Kontoyiannis D
Open Forum Infect Dis. 2024; 11(6):ofae133.
PMID: 38887472
PMC: 11181190.
DOI: 10.1093/ofid/ofae133.
Managing Infection Complications in the Setting of Chimeric Antigen Receptor T cell (CAR-T) Therapy.
Ahmed N, Oluwole O, Mahmoudjafari Z, Suleman N, McGuirk J
Clin Hematol Int. 2024; 6(2):31-45.
PMID: 38817309
PMC: 11086990.
DOI: 10.46989/001c.115932.
New anticancer therapeutics impact fungal pathobiology, infection dynamics, and outcome.
Palmucci J, Messina J, Tenor J, Perfect J
PLoS Pathog. 2023; 19(12):e1011845.
PMID: 38127685
PMC: 10735005.
DOI: 10.1371/journal.ppat.1011845.
Recognizing, defining, and managing CAR-T hematologic toxicities.
Rejeski K, Subklewe M, Locke F
Hematology Am Soc Hematol Educ Program. 2023; 2023(1):198-208.
PMID: 38066881
PMC: 10727074.
DOI: 10.1182/hematology.2023000472.
Invasive fusariosis.
Nucci M, Anaissie E
Clin Microbiol Rev. 2023; 36(4):e0015922.
PMID: 37937988
PMC: 10732078.
DOI: 10.1128/cmr.00159-22.
Case Report: Invasive fungal infection after anti-CD19 CAR-T cell therapy. Implication for antifungal prophylaxis.
Pennese E, Salutari P, Carriero L, Restuccia F, De Filippis A, De Luca G
Front Immunol. 2023; 14:1272798.
PMID: 37841271
PMC: 10574963.
DOI: 10.3389/fimmu.2023.1272798.
INSPIRED Symposium Part 3: Prevention and Management of Pediatric Chimeric Antigen Receptor T Cell-Associated Emergent Toxicities.
McNerney K, Hsieh E, Shalabi H, Epperly R, Wolters P, Hill J
Transplant Cell Ther. 2023; 30(1):38-55.
PMID: 37821079
PMC: 10842156.
DOI: 10.1016/j.jtct.2023.10.006.
Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
Stemler J, Mellinghoff S, Khodamoradi Y, Sprute R, Classen A, Zapke S
J Antimicrob Chemother. 2023; 78(8):1813-1826.
PMID: 37311136
PMC: 10393896.
DOI: 10.1093/jac/dkad143.
Case Report: Active tuberculosis infection in CAR T-cell recipients post CAR T-cell therapy: a retrospective case series.
Zhang P, Huang L, Zheng M, Zhang C, Wan D, Wei J
Front Cell Infect Microbiol. 2023; 13:1147454.
PMID: 37249982
PMC: 10210154.
DOI: 10.3389/fcimb.2023.1147454.
Infectious complications following CAR-t cell therapy for B cell non-Hodgkin lymphoma: a single-center experience and review of the literature.
Mercadal S, Gomez C, Lee C, Couriel D
Ann Hematol. 2023; 102(7):1837-1843.
PMID: 37246975
PMC: 10225770.
DOI: 10.1007/s00277-023-05131-7.
Infectious complications of chimeric antigen receptor (CAR) T-cell therapies.
Gea-Banacloche J
Semin Hematol. 2023; 60(1):52-58.
PMID: 37080711
PMC: 10119490.
DOI: 10.1053/j.seminhematol.2023.02.003.
